Foundation Wealth Management LLC acquired a new stake in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 19,471 shares of the biotechnology company's stock, valued at approximately $270,000.
Other institutional investors have also modified their holdings of the company. Creative Planning acquired a new stake in shares of Prothena in the third quarter worth approximately $350,000. GSA Capital Partners LLP acquired a new stake in Prothena during the 3rd quarter worth $484,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Prothena by 8.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,492 shares of the biotechnology company's stock worth $2,049,000 after purchasing an additional 9,666 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Prothena during the third quarter worth $210,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Prothena in the third quarter valued at about $432,000. Institutional investors and hedge funds own 97.08% of the company's stock.
Prothena Trading Down 5.8 %
PRTA stock traded down $0.85 during midday trading on Tuesday, hitting $13.75. 629,066 shares of the company's stock were exchanged, compared to its average volume of 395,558. Prothena Co. plc has a 1-year low of $11.70 and a 1-year high of $29.00. The business has a 50-day simple moving average of $14.39 and a two-hundred day simple moving average of $16.32. The stock has a market capitalization of $740.12 million, a PE ratio of -5.98 and a beta of -0.02.
Prothena (NASDAQ:PRTA - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.06). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The business had revenue of $2.12 million for the quarter, compared to analyst estimates of $7.53 million. As a group, research analysts expect that Prothena Co. plc will post -4.04 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on PRTA. StockNews.com upgraded shares of Prothena from a "sell" rating to a "hold" rating in a research report on Monday, February 24th. Chardan Capital restated a "buy" rating and issued a $40.00 price target on shares of Prothena in a research report on Friday, February 21st. Bank of America cut their price target on Prothena from $26.00 to $22.00 and set a "neutral" rating for the company in a report on Thursday, December 19th. HC Wainwright reissued a "buy" rating and set a $48.00 price objective on shares of Prothena in a research note on Friday, February 21st. Finally, Piper Sandler upped their target price on Prothena from $94.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Prothena has an average rating of "Moderate Buy" and an average price target of $55.00.
View Our Latest Research Report on Prothena
About Prothena
(
Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Featured Stories
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
